












4 Vaccine Safety Programs
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Vaccine Management Requirements
Clinical Staff Training Resources
Provider Onboarding Checklist
• Review VAMS onboarding considerations and document onboarding decisions via this required survey
no later than 48 hours of activation. Failure to do so will result in exclusion from COVID-19 Vaccination 
Program.
• Please note that vaccine supply requests are submitted in VAMS. 
• Attend the new provider onboarding session on Tuesdays from 11a-12:30p (click on link to access)
• Review VaccineFinder inventory reporting requirements. The organization contact email address from 
your section A form submission will receive an automated email from 
vaccinefinder@auth.castlighthealth.com within 48 hours. Please follow the set-up instructions. 
• Review DHEC’s phase 1a guidance to ensure your facility understands the target groups for vaccination
• Review v-safe and VAERS vaccine safety program considerations with all applicable vaccinating staff
• Review Pfizer and/or Moderna vaccine preparation and administration trainings with all vaccinating 
staff
• Review Pfizer and/or Moderna storage and handling trainings with all appropriate staff
• Ensure your storage unit is prepared to receive your first vaccine supply, including the placement of any 
approved continuous monitoring device, and utilization of temperature monitoring logs for twice-daily 
monitoring
• Review DHEC’s COVID-19 Vaccine Provider Webpage for training and resource documents for programs 
and systems listed above
• Attend a COVID-19 Vaccine Provider Town Hall Q&A on Wednesdays and Fridays from 11a-12p
Emails 
To ensure communications do not get delayed or blocked by 
organization servers, please work with your IT teams to 














1. The organization email listed from an enrolled provider’s section A form 
will receive an email from vaccinefinder@auth.castlighthealth.com
prompting them to complete their account registration in VaccineFinder. 
2. The email will look like the image to the right. Providers will click the 
“Create Account” link to complete VaccineFinder onboarding via the COVID 
Locating Health Provider Portal.
3. Open the registration email and click on the “Create Account” button. 
Please note, the link is a one-time use only and will expire after the 
first click.
4. Please ensure the link opens in one of the approved browsers (Safari, 
Chrome, or Microsoft Edge). You may need to right click, copy the link and 
paste it into one of the above approved browsers. 
5. You will be directed to the registration page where you will enter your 
username and create a new password.
6. Click submit, you'll be redirected back to the VaccineFinder login page. 





• Need help? Email the VaccineFinder helpdesk vaccinefinder@castlighthealth.com
• DHEC’s COVID-19 Provider Webpage
• Quick Start Guide for VaccineFinder Provider Setup
• COVID Locating Health Provider Portal Training for Providers
• Quick Start Guide VaccineFinder Inventory Reporting- Log Manually
• Quick Start Guide VaccineFinder Inventory Reporting- File Upload
• VaccineFinder COVID 19 Vaccine Provider Information website (includes training videos): 
https://vaccinefinder.org/covid-provider-resources
• CDC COVID 19 Vaccination Provider Support, Data and Reporting: 
https://www.cdc.gov/vaccines/covid-19/vaccination-provider-support.html
VAMS Overview
Vaccine Administration Management System (VAMS)
What is              ?
VAMS is a web-based system that allows jurisdictions and clinics to support 
vaccination operations for critical populations. SC may use this system 
primarily for phase 1 vaccination only.
▪ VAMS is a clinical system that records 
vaccine administration events. 
▪ VAMS sends the vaccine data to the 
corresponding immunization 
information system (IIS) and allows 
providers to fulfill all federal data 
reporting requirements. 
▪ All documented VAMS doses will 
transmit to SIMON (South 
Carolina’s statewide 
immunization registry)
▪ VAMS is “invite only” and is not open to 
the public.
✓ Can provide real-time reporting metrics
✓ Can request and track vaccine inventory
✓ Has dose-level accountability 
✓ Meets data security requirements 
✓ Can send reminders to vaccine 
recipients for follow-up doses and 
appointments
✓ Can provide a certificate of completion 
to the recipient
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Create Clinic Administrator 






































• Vaccine providers must request and track all 
inventory in VAMS
• Vaccine providers must document all 
administered vaccines within 24 hours
• Vaccine providers must have a vaccination 
















▪ Clinic Inventory 
Manager
▪ Clinic Healthcare 
Professional















What is the Vaccination Clinic Portal?
▪ An interface for clinics to support scheduling, immunization tracking, 
and inventory management
What are the Key Goals of the Vaccination Clinic Portal?
▪ Set up and manage clinic schedules and inventory
▪ Review recipient self-reported information during the healthcare 
encounter
The Vaccination Clinic Portal is not:
▪ An interface DHEC can access
▪ An interface recipients will access (they will have their own portal)
▪ An interface employers will access (they will have their own portal)
▪ A downloadable app (i.e., from App Store)
Clinic Type Description Considerations
Clinic
Settings with one permanent location for 
vaccination and vaccine storage. Vaccine 
supply can be either direct ship or 
redistributed from another location but is 
stored on-location.
• Vaccine recipients must pre-register in VAMS and 
schedule vaccination appointments in VAMS
• Site is considered “live” and searchable in VAMS
• Requires clinic schedule set up
• Allows inventory management based on scheduled 
appointments 
• VAMS provides 2nd dose reminders and 
notifications to recipients
• VAMS digitally provides pre-vaccination 





Clinic Type Description Considerations
Mobile
Settings with one permanent location for 
vaccine storage and multiple vaccine 
administration locations (daily offsite, 
temporary clinics). 
Vaccine is not stored at any offsite vaccine 
administration sites and is 
delivered/returned to permanent location 
for storage on the same day.
• Permanent location for vaccine storage is set up in 
VAMS as primary location for inventory 
management
• Clinic administrator adds multiple temporary 
vaccine clinic locations in VAMS
• Site is considered “live” and searchable in VAMS
• Vaccine recipients must pre-register in VAMS and 
search for your location to schedule vaccination 
appointments in VAMS 
• Requires clinic schedule set up (operating hours, 
etc)
• Allows inventory projections based on scheduled 
appointments 
• VAMS digitally provides pre-vaccination 
questionnaire, EUA, and vaccination certificate to 
recipients
• VAMS provides 2nd dose reminders and 
notifications to recipients
• *start and end dates of vaccination events cannot 






have the same start 
and end dates. Clinic 
schedules must be 
set up similar to the 




































Primary Role: Serve as vaccination clinic POC for jurisdiction and manage clinic
Processes Related Tasks
• Set up/manage clinic in VAMS • Establish yourself as clinic POC
• Verify and add clinic information such as physical and shipping 
address
• Set up/manage clinic schedule • Set up operating hours, appointment duration, and number of 
treatment stations
• Add/manage VAMS clinic users • Add clinic users in VAMS
• Set or edit user role permissions
• Remove users from VAMS
• Monitor/manage clinic vaccine 
inventory
• View clinic inventory
• Submit inventory requests to jurisdiction
• Find VAMS support or additional 
training resources when needed
• Search for your question in the FAQs on the Help page
Training Tools
▪ VAMS Clinic Staff User Manuals 
(clinic administrator should be 
familiar with all clinic roles)
▪ VAMS Clinic Setup Quick Start 
Guide
▪ 1:1 Support with SC DHEC POC
▪ Attend DHEC Townhall Q&A 
sessions
▪ View training videos
What does the clinic administrator need to learn in VAMS? How will they learn?
Considerations: clinic administrators can fulfill this role for multiple locations
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Clinic Inventory Manager
Primary Role: Monitor and manage clinic’s vaccine inventory
Processes Related Tasks
• Manage clinic vaccine inventory • View clinic inventory
• Submit inventory requests to jurisdiction
• Find VAMS support or additional 
training resources when needed
• Search for your question in the FAQs on the Help page
Training Tools
▪ VAMS Clinic Inventory Manager 
User Manual
▪ Demo Presentation Videos
▪ VAMS FAQs





Primary Role: Administer vaccine to recipients
Processes Related Tasks
• View/manage recipient appointments • View scheduled appointments
• Administer vaccine • Access recipient record 
• Review recipient record 
• Add note to recipient record
• Review previously added notes
• Record decision to administer vaccine
• Log vaccination 
• Log waste
• Find VAMS support or additional 
training resources when needed
• Search for your question in the FAQs on the Help page
How will they learn?
Training Tools
▪ VAMS Clinic Healthcare 
Professional User Manual
▪ Demo Presentation Videos
▪ VAMS Pocket Manual
▪ VAMS FAQs





Primary Role: Welcome and check in recipients
Processes Related Tasks
• Check in vaccine recipients • Use QR code to locate recipient appointment
• Manually locate recipient appointment
• Validate recipient identification
• Validate pre-vaccination questionnaire compliance
• Modify/cancel recipient appointments • View appointment status
• Cancel appointments 
• Auto-cancellation for no-show appointments 
• Find VAMS support or additional 
training resources when needed
• Search for your question in the FAQs on the Help page
Training Tools
▪ VAMS Clinic Front Desk User 
Manual
▪ Demo Presentation Videos
▪ VAMS FAQs




























Activate and Set 
Up Clinic
Step 1
Create Clinic Administrator 
































































activates and sets 
up clinic locations
Step 1
Creates Clinic Administrator 







































Clinic Type Description Considerations
Third-party
Clinics in settings for administering 
vaccine to recipients unable to access 
VAMS (i.e. nursing homes, correctional 
facility) OR for locations that desire to use 
a pre-existing notification, scheduling, and 
pre-screening system for vaccine 
recipients
• Vaccine recipients do not use VAMS to pre-register 
or schedule appointments
• Does NOT require the use of the 
Employer/Organization Portal
• Clinic location is not searchable by VAMS users
• Requires manual inventory tracking for 2nd dose 
needs
• Facilities must coordinate and communicate 
recipient vaccination events internally or through 
existing means
• Requires collection of demographic and screening 
information from recipients prior to vaccination OR 
at the time of the vaccination
• Requires manually adding each recipient, or bulk 
uploading a list of pre-screened recipients, prior to 
vaccination
• Facility is responsible for distributing the EUA 
sheet, issuing 2nd dose reminders, and 
coordinating 2nd dose events

























Activate and Set 
Up Clinic
Step 1




















• Determine the clinic location’s point of contact (POC) who will serve as the 
clinic administrator (default is primary vaccine coordinator who can re-assign if 
needed)






• Review user manuals and training videos on DHEC’s COVID-19 
Provider Webpage
• Quick Start Guide for Clinic Set-up
• Clinic administrator and employer coordinator role demo videos
Employer and Organization 
Portal
VAMS Overview
Applies to non-Third Party Clinics Only
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STEP 3 Your Portal: Employer and Organization 
Portal
What is the Employer and Organization Portal?
• An interface for employers/organizations to upload 
employee/staff information
What are the Key Goals of the Employer and Organization 
Portal?
• Identify potential vaccine recipients to register for COVID-19 
vaccination through the Recipient Portal
The Employer and Organization Portal is not:
• An interface clinics will access (they will have their own portal)
• An interface recipients will access (they will have their own 
portal)
• An interface jurisdictions or CDC will access (they will have their 
own portal)
• A downloadable app (i.e., from the App Store)
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Employer Coordinator (EC)
Primary Role: Register employer and initiate registration for employees
What does the Employer Coordinator need to learn in VAMS?
• Complete employer registration • Have all employer contact information ready to input
• Review and submit employer registration
• Upload employees into VAMS • Add employees individually or in a bulk upload
• View employee roster
• Find VAMS support or additional 
training resources when needed
• Search for your question in the FAQs on the Help page
How will they learn?
Training Tools
▪ VAMS Model Training Plan
▪ Employer Coordinator User Manual






Personalized Employee Registration Option 1
The EC adds employees via manual addition, either one at a time or bulk 
upload, generating an auto email notification to identified employee/staff
Pros
• No email address restrictions
• Cannot be forwarded to others




The EC opts to have a common registration link using up to three (3) linked email address 
domains (i.e. @dhec.sc.gov)
1. EC crafts email messaging and sends organization-specific registration link to targeted 
employees, or EC can post the link for all employees to access via intranet or other source
2. Employees access the link and enter their organization name and email
3. VAMS will validate the email entered by the employee matches one of the specific 
organization domains
4. VAMS will send a unique registration link to the employee email
5. Employees click the registration link and start the standard registration flow
Pros
• Potentially reduces administrative burden on EC
• EC can control messaging to employees about registration
Cons
• Third-party email domains cannot be used for PER (gmail.com; yahoo.com)
• Employees cannot change their email during registration
• Once PER is selected, DHEC cannot edit the organization’s record in VAMS
• Targeted employees can forward link to other non-targeted employees in 
the organization with the same email domain
VAMS Onboarding Decisions
DHEC will need to know:
• The organization’s point of contact (POC) information 
who will serve as the EC
• First name, last name, and email address
• Organization category
• Inpatient healthcare providers
• Outpatient healthcare providers
• Employee registration process option
• Option 1: Personalized registration link 
• Option 2: Policy-Enabled Registration 
Complete this VAMS 
onboarding survey within 48 
hours of activation notice 




• COVID-19 Vaccine Primary and Back-up Coordinators must monitor 
and document temperatures of storage units containing COVID-19 
vaccines twice daily using approved temperature logs. 
• Ultra-cold vaccine storage (Celsius)
• Ultra-cold vaccine storage (Fahrenheit)
• Refrigerator or Freezer vaccine storage
• COVID-19 Vaccine Primary and Back-up Coordinators must download 
continuous temperature monitoring device reports weekly
• Temperature logs are also required for any vaccine redistribution 
transport 
• Submit both temp logs and DDL reports to 
COVIDProviderEnrollment@dhec.sc.gov every Friday by COB. 
• Include Facility Name + Temp Logs in subject line
Temperature Excursions-
during shipment
• Providers must immediately report any 
temperature excursions during shipment
• Pfizer Shipments: 
• Pfizer: 1-877-829-2619 or cvgovernment@Pfizer.com
• Moderna Shipments:
• McKesson: 1-833-272-6635 (M-F, 8a-8p/ET)
• After-hours email COVIDVaccineSupport@McKesson.com
Temperature Excursions-
post-shipment
• Providers must immediately report any 




• Upon resolution, providers must submit a 
Vaccine Troubleshooting Record to 
COVIDProviderEnrollment@dhec.sc.gov that 
documents the event and any associated 
case number
Inventory Reporting
• Adjust (Add/Reduce) all vaccine inventory and waste in VAMS
• Upon delivery receipt
• Track extra Pfizer doses (estimated 1 or 2 extra vial) or 
Moderna doses (estimated potential for 1 extra per vial) 
pulled from MDVs 
• Add “vials” in VAMS to accommodate the overages
• Every 5 Pfizer doses= 1 vial
• Every 10 Moderna doses= 1 vial
• Report daily on-hand inventory doses to the COVID Health 
VaccineFinder portal (Mon-Sun)
VAMS Inventory requests
• When placing your weekly inventory requests in VAMS:
• Select your facility’s vaccine type
• Add quantity desired
• In the notes section:
• Add number of your phase 1a staff to be vaccinated (initial 
doses)
• Include any 2nd doses needed for that week 
• Include specific names of external partners that your facility 
has agreed to vaccinate
• Add estimated number of phase 1a community members 
your site intends to vaccinate, or has the potential to 
vaccinate, within that week
• Please refer to your submitted VAMS inventory request for 
confirmation and details (ensure to click FOLLOW to receive 
















• Smartphone-based text messaging program 
designed for vaccine recipients
• Recipients can opt-in and quickly tell CDC if they 
have any side effects
• Providers must post v-safe poster during 
vaccination events and share information
• See DHEC’s COVID-19 provider website to 
download v-safe poster and information sheets. 
Clinical Staff Training
Interim Clinical Considerations for use of mRNA COVID-19 
Vaccines Currently Authorized in the United States
Authorized age groups
• Under the EUAs, the following age groups 
are authorized to receive vaccination:
• Pfizer-BioNTech: ages ≥16 years
• Moderna: ages ≥18 years
• Children and adolescents outside of these 
authorized age groups should not receive COVID-
19 vaccination at this time
Administration
• mRNA vaccines are not live vaccines
• The mRNA COVID-19 vaccine series consist of two doses administered 
intramuscularly:
• Pfizer-BioNTech (30 µg, 0.3 ml each): three weeks (21 days) apart
• Moderna (100 µg, 0.5 ml): one month (28 days) apart
• Second doses administered within a grace period of ≤4 days from the 
recommended date for the second dose are considered valid; 
however, doses administered earlier do not need to be repeated. 
• The second dose should be administered as close to the 
recommended interval as possible. However, there is no maximum 
interval between the first and second dose for either vaccine.
Interchangeability with other 
COVID-19 products
• Either of the currently authorized mRNA COVID-19 vaccines 
can be used when indicated; ACIP does not state a product 
preference. 
• However, these mRNA COVID-19 vaccines 
are not interchangeable with each other or with other COVID-
19 vaccine products. The safety and efficacy of a mixed-
product series have not been evaluated. 
• Both doses of the series should be completed with the same 
product. However, if two doses of different mRNA COVID-19 
vaccine products are inadvertently administered, no additional 
doses of either product are recommended at this time. 
Coadministration with other 
vaccines
• Given the lack of data on the safety and efficacy of mRNA 
COVID-19 vaccines administered simultaneously with 
other vaccines, the vaccine series should be 
administered alone, with a minimum interval of 14 days 
before or after administration with any other vaccines. 
• If mRNA COVID-19 vaccines are inadvertently 
administered within 14 days of another vaccine, doses do 
not need to be repeated for either vaccine.
Vaccination of persons with SARS-CoV-
2 infection or exposure
• Persons with current or prior hx of SARS CoV-2-infection
• Vaccination should be offered to persons regardless of 
history of prior symptomatic or asymptomatic SARS-CoV-2 
infection.
• Vaccination of persons with known current SARS-CoV-2 
infection should be deferred until the person has 
recovered from the acute illness (if the person had 
symptoms) and criteria have been met for them to 
discontinue isolation.
• While there is otherwise no recommended minimum 
interval between infection and vaccination, current 
evidence suggests that reinfection is uncommon in the 90 
days after initial infection. Thus, persons with documented 
acute SARS-CoV-2 infection in the preceding 90 days may 
delay vaccination until near the end of this period, if 
desired
Vaccination of persons with SARS-CoV-
2 infection or exposure
• Persons who previously received passive antibody therapy for 
COVID-19
• Currently, there are no data on the safety and efficacy of mRNA COVID-19 
vaccines in persons who received monoclonal antibodies or convalescent 
plasma as part of COVID-19 treatment. 
• Based on the estimated half-life of such therapies as well as evidence 
suggesting that reinfection is uncommon in the 90 days after initial 
infection, vaccination should be deferred for at least 90 days, as a 
precautionary measure until additional information becomes available, to 
avoid interference of the antibody treatment with vaccine-induced 
immune responses.
Vaccination of persons with underlying 
medical conditions
• Immunocompromised persons
• Persons with HIV infection or other immunocompromising conditions, or 
who take immunosuppressive medications or therapies might be at 
increased risk for severe COVID-19. Data are not currently available to 
establish vaccine safety and efficacy in these groups. 
• Persons with stable HIV infection were included in mRNA COVID-19 
vaccine clinical trials, though data remain limited. 
• Immunocompromised individuals may still receive COVID-19 vaccination if 
they have no contraindications to vaccination. However, they should be 
counseled about the unknown vaccine safety profile and effectiveness in 
immunocompromised populations, as well as the potential for reduced 
immune responses and the need to continue to follow all current 
guidance to protect themselves against COVID-19 (i.e. mask, social 
distancing, hand hygiene)
Vaccination of persons with underlying 
medical conditions
• Persons with autoimmune conditions
• No data are currently available on the safety and efficacy of mRNA COVID-
19 vaccines in persons with autoimmune conditions, though these 
persons were eligible for enrollment in clinical trials. 
• No imbalances were observed in the occurrence of symptoms consistent 
with autoimmune conditions or inflammatory disorders in clinical trial 
participants who received an mRNA COVID-19 vaccine compared to 
placebo. 
• Persons with autoimmune conditions who have no contraindications to 
vaccination may receive an mRNA COVID-19 vaccine
Vaccination of persons with underlying 
medical conditions
• Persons with a history of Guillain-Barré syndrome (GBS)
• To date, no cases of GBS have been reported following vaccination among 
participants in the Pfizer-BioNTech or Moderna COVID-19 vaccines clinical 
trials. 
• With few exceptions, Advisory Committee on Immunization Practices 
(ACIP) general best practice guidelines for immunization does not include 
history of GBS as a contraindication or precaution to vaccination. 
• Persons with a history of GBS may receive an mRNA COVID-19 vaccine 
unless they have a contraindication to vaccination. 
• Any occurrence of GBS following mRNA COVID-19 vaccination should be 
reported to the Vaccine Adverse Event Reporting System (VAERS).
Vaccination of persons with underlying 
medical conditions
• Persons with a history of Bell’s palsy
• Cases of Bell’s palsy were reported following vaccination in participants in 
both the Pfizer-BioNTech and Moderna COVID-19 vaccines clinical trials.
• However, the FDA does not consider these to be above the frequency 
expected in the general population and has not concluded that these 
cases were causally related to vaccination. 
• Post-authorization safety surveillance will be important to further assess 
any possible causal association. 
• In the absence of such evidence, persons with a history of Bell’s palsy may 
receive an mRNA COVID-19 vaccine unless they have a contraindication to 
vaccination. 
• Any occurrence of Bell’s palsy following mRNA COVID-19 vaccination 
should be reported to VAERS
Vaccination of pregnant women
• There are currently few data on the safety of COVID-19 vaccines, 
including mRNA vaccines, in pregnant people.
• The mRNA in the vaccine is degraded quickly by normal cellular 
processes and does not enter the nucleus of the cell. Based on 
current knowledge, experts believe that mRNA vaccines are unlikely to 
pose a risk to the pregnant person or the fetus.
• If pregnant people are part of a group that is recommended to receive 
a COVID-19 vaccine (e.g., healthcare personnel), they may choose to 
be vaccinated. A conversation between the patient and their clinical 
team may assist with decisions regarding the use of a mRNA COVID-19 
vaccine, though a conversation with a healthcare provider is not 
required prior to vaccination.
• There is no recommendation for routine pregnancy testing before 
receipt of a COVID-19 vaccine. Those who are trying to become 
pregnant do not need to avoid pregnancy after mRNA COVID-19 
vaccination.
Vaccination of lactating women
• There are no data on the safety of COVID-19 vaccines in lactating 
people or the effects of mRNA COVID-19 vaccines on the breastfed 
infant or milk production/excretion. 
• mRNA vaccines are not thought to be a risk to the breastfeeding 
infant. 
• A lactating person who is part of a group recommended to receive a 
COVID-19 vaccine (e.g., healthcare personnel) may choose to be 
vaccinated
Patient Counseling: Vaccine Efficacy
• Preliminary data suggest high vaccine efficacy in preventing 
COVID-19 following receipt of two doses of mRNA COVID-19 
vaccine (Pfizer-BioNTech: 95.0% [95% CI: 90.3%, 97.6%]; 
Moderna: 94.1% [95% CI: 89.3%, 96.8%]). 
• Limited data are currently available regarding the efficacy of a 
single dose.
• Patients should be counseled on the importance of completing 
the two-dose series (of the same vaccine product) to optimize 
protection
Patient Counseling: Reactogenicity
• Before vaccination, providers should counsel mRNA COVID-19 vaccine 
recipients about expected local (e.g., pain, swelling, erythema at the 
injection site, localized axillary lymphadenopathy on the same side as 
the vaccinated arm) and systemic (e.g., fever, fatigue, headache, chills, 
myalgia, arthralgia) post-vaccination symptoms.
• Most systemic post-vaccination symptoms are mild to moderate in 
severity, occur within the first three days of vaccination, and resolve 
within 1–3 days of onset. 
• These symptoms are more frequent and severe following the second dose and 
among younger persons compared to older persons
• Antipyretic or analgesic medications (e.g., acetaminophen, non-
steroidal anti-inflammatory drugs) may be taken for the treatment of 
post-vaccination local or systemic symptoms, if medically appropriate.
• However, routine prophylactic administration of these medications for the purpose 
of preventing post-vaccination symptoms is not currently recommended, as 
information on the impact of such use on mRNA COVID-19 vaccine-induced antibody 
responses is not available at this time
Management of allergic 
reactions
• Appropriate medical treatment used to manage immediate allergic 
reactions must be immediately available in the event that an acute 
anaphylactic reaction occurs following administration of an mRNA 
COVID-19 vaccine. 
• Vaccine providers should observe patients with a history of 
anaphylaxis (due to any cause) for 30 minutes after vaccination. 
• All other persons should be observed for 15 minutes after vaccination 
to monitor for the occurrence of immediate adverse reactions.
• Review CDC’s Considerations: Preparing for the Potential Management 
of Anaphylaxis at COVID-19 Vaccination Sites
Pfizer- BioNTech COVID-19 Vaccine
Click here to visit the Resource Page:
• Vaccine administration overview
• Pre-vaccination screening form
• Standing orders
• Preparation and Administration Summary
• Mixing Diluent and Vaccine Poster
• Storage and Handling 
• Storage and handling summary
• Delivery checklist
• Storage and handling labels
• Ultra-cold vaccine storage temperature monitoring logs
• Pfizer Beyond Use Date (BUD) Guidance and Labels (refrigerated 
storage)
Moderna COVID-19 Vaccine
Click here to visit the Resource Page:
• Vaccine administration overview
• Standing Orders
• Preparation and Administration Summary
• Storage and Handling 
• Vaccine Expiration Date Tracking Tool
• Storage and Handling labels
• Beyond-Use-Date Guidance and Labels
• Freezer temperature logs (C° and F°)
Clinical Guidance Resource
If a healthcare professional at your facility has 
clinical guidance needs, please contact:
• Clinician On-Call Center:
• Call 800-CDC-INFO (800-232-4636) and ask for the Clinician On-
Call Center. 
• Email: eocevent168@cdc.gov
• The Clinician On-Call Center is a 24-hour hotline with trained CDC 
clinicians standing by to answer COVID-19 questions from healthcare 
personnel on a wide range of topics, such as diagnostic challenges, 
clinical management, and infection prevention and control. 
COVID-19 Vaccination Program
Immunization Branch
Provider Onboarding, Education and Support Team: 
VAMS@dhec.sc.gov
